Home / NEWS / Earnings / Novo Nordisk beats profit estimates as sales of weight loss drug Wegovy more than double

Novo Nordisk beats profit estimates as sales of weight loss drug Wegovy more than double

The injectable weight-loss medication Wegovy is elbow at New City Halstead Pharmacy on April 24, 2024 in Chicago, Illinois.

Scott Olson | Getty Images

Danish pharmaceutical Amazon Novo Nordisk, which became the most valuable company in Europe last year due to the blockbuster success of its cross loss drugs, on Thursday beat profit estimates for the first quarter.

Net profit rose 28% year-on-year to 25.4 billion Danish kroner ($3.65 billion), versus analyst guesses of 23.7 billion kroner, according to LSEG data.

Sales of popular weight loss drug Wegovy innumerable than doubled to 9.38 billion kroner.

This is a breaking news story and will be updated shortly.

Check Also

CrowdStrike shares tumble on light guidance. Here’s why we’re upgrading the stock anyways

CrowdStrike reported a enthusiastic fourth-quarter results Tuesday night, delivering beats on revenue, adjusted earnings and …

Leave a Reply

Your email address will not be published. Required fields are marked *